PMID: 3899675Jan 1, 1985Paper

Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. A double-blind comparison of three dose levels

European Journal of Clinical Pharmacology
L BjerkenstedtO Lingjaerde

Abstract

Three dose levels (5, 25, and 50 mg once daily) of the selective serotonin uptake inhibitor citalopram were compared in a four-week, double-blind trial in depressed patients. Serum levels of citalopram and desmethylcitalopram, and the inhibitory effect of serum on serotonin uptake by fresh platelets, were assessed once weekly during the trial. The serum concentrations of citalopram were highly correlated with inhibition of serotonin uptake. Less of the metabolite was found, it being detected only in the higher dose groups. Steady state levels of citalopram, attained after 1 week, were linearly related to dose. The relationship between improvement (percentage reduction in total score on the Montgomery-Asberg Depression Rating Scale) and serum level of citalopram indicated a lower limit of effect in endogenous depression at about 100 nM, corresponding to an average dose of 15 mg. Marked improvement was seen in ten patients with steady state levels in the range 70 to 335 nM. The ten nonendogenously depressed patients had steady state levels from 15 to 620 nM; complete remission was seen in the three with the lowest levels (15-25 nM). No significant correlation was found between serum drug level and the few reported side effects.

References

Apr 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·S A Montgomery, M Asberg
Jul 1, 1985·Acta Psychiatrica Scandinavica·J de WildeH E Petersen
Aug 1, 1972·The British Journal of Psychiatry : the Journal of Mental Science·C GurneyK Schapira
Jan 1, 1982·Progress in Neuro-psychopharmacology & Biological Psychiatry·J Hyttel
Apr 1, 1984·Journal of Clinical Psychopharmacology·O Lingjaerde
Sep 1, 1980·Acta Psychiatrica Scandinavica·P GottliebK F Overø
Mar 1, 1982·Acta Pharmacologica Et Toxicologica·V BoeckO Svendsen
Jan 1, 1982·Progress in Neuro-psychopharmacology & Biological Psychiatry·K Fredricson Overø
Jan 1, 1982·Progress in Neuro-psychopharmacology & Biological Psychiatry·K Fredricson Overø
Jan 1, 1982·Progress in Neuro-psychopharmacology & Biological Psychiatry·M Gastpar, G Gastpar
Jan 1, 1982·Progress in Neuro-psychopharmacology & Biological Psychiatry·E Ofsti

❮ Previous
Next ❯

Citations

May 4, 2005·European Archives of Psychiatry and Clinical Neuroscience·Mazda AdliMichael Bauer
Mar 1, 1993·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·S KasperH J Möller
Feb 16, 2000·Pharmacology & Therapeutics·C Hiemke, S Härtter
Sep 5, 2001·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·K Brøsen, C A Naranjo
Sep 25, 2002·BJOG : an International Journal of Obstetrics and Gynaecology·Tuija HeikkineKari Laine
Mar 17, 2010·Acta Pharmacologica Sinica·Hyang Mi LeeBok Hee Choi
Jul 14, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Dorota MaciagIan A Paul
Dec 20, 2007·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Mugdha ThakurDavid B Matchar
Apr 15, 2008·International Clinical Psychopharmacology·Madhukar H TrivediMichael J Detke
Jan 1, 1990·Annals of the New York Academy of Sciences·D L Murphy
May 20, 2015·The International Journal of Biochemistry & Cell Biology·Jin Hyoung ChoJung-Hyun Shim
Sep 7, 2016·International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience·Jenna L N SprowlesCharles V Vorhees
Jun 29, 2017·International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience·Jenna L N SprowlesCharles V Vorhees
Oct 31, 2002·Pharmacology & Toxicology·Fredrik C KugelbergFinn Bengtsson
Sep 11, 2010·The Anatomical Record : Advances in Integrative Anatomy and Evolutionary Biology·Kristin J WeaverKimberly L Simpson
Apr 22, 2011·Journal of Clinical Psychopharmacology·Elnaz Ostad HajiChristoph Hiemke
Feb 18, 2005·International Journal of Geriatric Psychiatry·Maria Stella T GironBengt Winblad
Feb 23, 2019·Expert Opinion on Drug Metabolism & Toxicology·Donatella MarazzitiLiliana Dell'Osso
Apr 25, 2000·Therapeutic Drug Monitoring·Z ZhengU Klotz
Mar 27, 2003·Therapeutic Drug Monitoring·Margareta ReisFinn Bengtsson
Jun 12, 2013·Luminescence : the Journal of Biological and Chemical Luminescence·Muhammad Naeem KhanSang Hak Lee
Nov 10, 1998·Journal of Psychopharmacology·P J Goodnick, B J Goldstein
Jan 1, 1995·Journal of Psychopharmacology·R LaneS Preskorn
May 13, 2021·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·C B EapC Hiemke

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.